Loading
Summit Therapeutics Shares Surge on Akeso's Positive Cancer Trial Data
TrustFinance Global Insights
Th08 26, 2026
2 min read
0
Key Trial Success Boosts Summit Therapeutics
Summit Therapeutics Inc. (NASDAQ:SMMT) shares surged 7.75% Wednesday following positive top-line results from a Phase III cancer study by its partner, Akeso Inc., focusing on advanced biliary tract cancer.
Akeso's HARMONi-GI1 Study Details
Akeso announced its HARMONi-GI1 study met its primary endpoint: ivonescimab plus chemotherapy achieved statistically significant overall survival superiority as a first-line treatment for advanced biliary tract cancer. Key secondary endpoints, including progression-free survival and objective response rate, were also met in the 682-patient China-based study. Ivonescimab remains investigational in Summit’s U.S. and European territories.
Analyst Perspectives and Market Outlook
H.C. Wainwright analyst Mitchell S. Kapoor maintained a Neutral rating, awaiting detailed overall survival hazard ratios. Guggenheim analyst Brad Canino reiterated a Buy rating with a $38.00 price target. Canino emphasized these results strengthen the argument for ivonescimab's consistent effect, crucial for its broader lung cancer implications, despite biliary tract cancer being a smaller market. Detailed study results are expected at an upcoming medical congress.
Summary and Next Steps
The positive Phase III data from Akeso signals promising developments for Summit Therapeutics, reinforcing confidence in ivonescimab's efficacy. Future focus will be on the release of detailed results and further market progress.
Frequently Asked Questions
Q: Why did Summit Therapeutics' stock increase?
A: The stock gained following positive top-line results from a Phase III cancer study by partner Akeso Inc. for advanced biliary tract cancer.
Q: What did Akeso's HARMONi-GI1 study demonstrate?
A: It showed that ivonescimab plus chemotherapy achieved statistically significant overall survival superiority as a first-line treatment for advanced biliary tract cancer.
Q: Is ivonescimab approved globally?
A: Ivonescimab is approved for non-small cell lung cancer in China but is investigational in Summit's licensed territories like the U.S. and Europe.
Text : Source
Investing.com
Written by
TrustFinance Global Insights
AI-assisted editorial team by TrustFinance curating reliable financial and economic news from verified global sources.
Tags:
Best pick of the Week
Related Articles
